ClinicalTrials.gg
CompletedNCT00650572Updated May 7, 2020

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

A Phase 1 interventional study of ARRY-380, HER2 inhibitor; oral in Cancer, sponsored by Seagen Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1 study during which patients with advanced HER2+ solid malignancies or HER2+ metastatic breast cancer will receive investigational study drug ARRY-380.

This study has 2 parts. In the first part, patients with advanced HER2+ solid malignancies, who have already received at least one previous standard therapy, will receive increasing doses of study drug in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 30 patients from the US will be enrolled in Part 1 (Completed).

In the second part of this study, patients with HER2+ metastatic breast cancer, who have already received at least one previous standard therapy, will receive the best dose of study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 20 patients from the US will be enrolled in Part 2 (Active, not recruiting).

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • human epidermal growth factor receptor 2
  • epidermal growth factor receptor
  • EGFR
  • type I receptor tyrosine kinase
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 50 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria (Part 1 and Part 2):

  • Histological or cytological evidence of + cancer (Part 1) or HER2+ breast cancer (Part 2).
  • Patients should have received at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy (patients with HER2+ breast cancer and with clinical indication for trastuzumab or lapatinib should have received prior therapy with trastuzumab and lapatinib, if available).
  • (ECOG) performance status (PS) between 0 and 2.
  • Additional criteria exist.

Key Exclusion Criteria (Part 1 and Part 2):

  • Uncontrolled or symptomatic (patients may be considered adequately controlled if on a stable dose for at least 30 days).
  • Treatment with an medicinal product or device within 30 days prior to first dose of study drug.
  • Radiotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites).
  • Chemotherapy within 21 days prior to first dose of study drug.
  • Major surgery within 30 days prior to first dose of study drug.
  • Known positive serology for the (HIV), and/or active .
  • Additional criteria exist.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    ARRY-380

    Drug: ARRY-380, HER2 inhibitor; oral

Interventions

  • DrugARRY-380, HER2 inhibitor; oral

    Drug page: Tucatinib

    Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.

06

What researchers measure

Primary outcomes

  1. Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.

    Time frame: Part 1, one year; Part 2, one year

  2. Establish the maximum tolerated dose (MTD) of the study drug.

    Time frame: Part 1, one year

  3. Characterize the pharmacokinetics of the study drug.

    Time frame: Part 2, one year

  4. Assess amplification/expression of HER2 in archival and tumor tissues.

    Time frame: Part 2, one year

Secondary outcomes

  1. Characterize the pharmacokinetics of the study drug.

    Time frame: Part 1, one year

  2. Assess changes in tumor markers.

    Time frame: Part 1, one year

  3. Assess the efficacy of study drug in terms of tumor response and duration of response.

    Time frame: Part 1, one year; Part 2, one year

  4. Assess expression of growth factor pathway proteins in archival and tumor tissues.

    Time frame: Part 2, one year

07

Study locations

4 sites
  • The University of Colorado Cancer Center
    Aurora, Colorado, United States
  • The University of Texas, MD Anderson Cancer Center
    Houston, Texas 77230, United States
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • Cancer Centre of Southeastern Ontario at Kingston General Hospital
    Kingston, Ontario K7L 5P9, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 2, 2008
Start
May 2008
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00650572
Lead sponsor
Seagen Inc.
Collaborators
Array BioPharma
Responsible party
Sponsor
First posted
Apr 2, 2008
Start date
May 2008
Primary completion
Mar 2013
Completion
Mar 2013
Last update
May 7, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion